Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of AD-218 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating AD-218 for mixed dyslipidemia is currently recruiting. Sponsor: Addpharma Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Dyslipidemia

Drugs mentioned

• AD-218

Snippet

Sponsor: Addpharma Inc. | Conditions: Mixed Dyslipidemia | Phase 3 | Status: RECRUITING